SGLT2 inhibitors are a class of drugs used primarily to help manage type 2 diabetes by lowering blood sugar levels.

These medications work by causing "glycosuria," where excess sugar is excreted through urine. They target a protein in the kidneys called SGLT2, a glucose transporter, effectively enabling users to release significant amounts of sugar that would otherwise be reabsorbed into the bloodstream.

The body often compensates for this sugar loss by increasing gluconeogenesis, a process where the body converts protein into sugar, potentially leading to muscle mass loss.

While SGLT2 inhibitors can be beneficial, indiscriminate or incorrect use can lead to significant side effects.

In individuals with significantly lowered insulin production, such as those in the advanced stages of diabetes, these drugs can cause diabetic ketoacidosis—an unsafe rise in ketone levels due to insufficient insulin to control fat metabolism.

Diabetic ketoacidosis represents a serious medical condition that can occur under certain conditions with SGLT2 inhibitor use.

Patients on SGLT2 inhibitors should receive guidance on lifestyle adjustments, such as diet and exercise, to improve insulin resistance and prevent adverse effects. Routine monitoring of insulin levels is essential to avoid complications like ketoacidosis.

SGLT2 inhibitors offer potential benefits in managing diabetes by reducing blood sugar levels and supporting fat metabolism. However, they should be used with caution and under proper medical supervision to prevent muscle loss and serious complications.